News

The French drugmaker is considering building a U.S. production site, joining other European companies looking across the pond when planning new investments.

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.

Sticky inflation is quietly rewarding a specific group of stocks with decades of uninterrupted dividend growth, and Wall Street's top analysts say five of them are built to profit no matter how long rising prices persist.

The investment-grade bond market faces a busy September, but demand for corporate debt suggests anxiety about heavy supply may be overblown, according to Kelsey Berro, a portfolio manager at JPMorgan Asset Management.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

The stock is up just 8% this year and could prove to be an undervalued buy.

REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic

Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.

AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.

Moby summary of AbbVie Inc.'s Q2 2026 earnings call

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

Earnings Data Deluge

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p

Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates

The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share

AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.

Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.

Asking for a Trend Host Josh Lipton previews what investors should be on the lookout for on Friday, July 31, including earnings from energy giants Exxon (XOM), Chevron (CVX), and biopharma AbbVie (ABBV) as well as the latest read on consumer sentiment.